STOCK TITAN

Alector to Participate in Upcoming Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Alector, Inc. (ALEC) to participate in multiple investor conferences to discuss immuno-neurology advancements. Webcasts available on their website for 90 days post-event.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

  • TD Cowen 44th Annual Health Care Conference (Boston, Massachusetts)
    • Tuesday, March 5, 2024, at 10:30 a.m. ET, panel
  • Leerink Partners Global Biopharma Conference (Miami, Florida)
    • Tuesday, March 12, 2024, at 10:40 a.m. ET, corporate presentation
  • Barclays 26th Annual Global Healthcare Conference (Miami, Florida)
    • Wednesday, March 13, 2024, at 2:05 p.m. ET, fireside chat
  • Stifel 2024 CNS Days (Virtual)
    • Tuesday, March 19, 2024, at 11:30 a.m. ET, fireside chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com


FAQ

When will Alector, Inc. participate in the TD Cowen 44th Annual Health Care Conference?

Alector, Inc. will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 10:30 a.m. ET.

Where can investors watch webcasts of Alector, Inc.'s conference presentations?

Investors can watch webcasts of Alector, Inc.'s conference presentations on the 'Events & Presentations' page within the Investors section of the Alector website at http://investors.alector.com.

For how long will replays of the webcasts be available on Alector, Inc.'s website?

Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

Alector, Inc.

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Stock Data

508.91M
75.76M
9.93%
79.61%
6.76%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About ALEC

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.